Axcynsis Therapeutics to Present Two Posters on Anti-CLDN6 and Anti-ALPP/ALPPL2 Antibody Therapeutics at American Association for Cancer Research (AACR) Annual Meeting 2025
Singapore, April 21, 2025 – Axcynsis Therapeutics is at the [...]
Singapore, April 21, 2025 – Axcynsis Therapeutics is at the [...]
AT03-65 is the first program utilizing AxcynDOTTM, a proprietary payload [...]
Singapore, December 31, 2024 - We are thrilled to announce [...]
Axcynsis Therapeutics won 2nd place in BCIC Annual Pitch Competition [...]
Axcynsis, Next Generation of ADC Singapore, December 26, 2023 – [...]
We are happy to share that our Founder and CEO, [...]
We are honored and proud to receive the GHP [...]
Join our founder and CEO, Dr Zou Bin, together [...]
We are gearing up for the WuXi AppTec BOLD [...]
Published in Business Times 21 June 2023: "Wanted: experts [...]